Forecast

The analysts' average price target is €11.71 (+47.85%). The median is €10.36 (+30.81%).

Buy	19
Hold	6
Sell	1

News Go to news feed

Arvinas: Q1 revenue plunges, EPS beats expectations and stock rises in premarket

Arvinas reported Q1 2026 revenue of $15.6 million (estimate $17.16 million, Q1 2025: $188.8 million), mainly due to the restructuring of the partnership with Pfizer. Earnings per share were -$0.90, beating the expected -$0.93. The company significantly cut R&D and general & administrative expenses, extended its cash runway into the second half of 2028, and points to FDA approval for VEPPANU as a key milestone. The stock rose 1.45% in premarket trading to $9.80. » More on de.investing.com
Arvinas closes license deal with Rigel and Pfizer for VEPPANU rights

Arvinas and Pfizer received from Rigel the exclusive global rights to develop, manufacture and commercialize VEPPANU (vepdegestrant) for ER-positive, HER2-negative, ESR1-mutant advanced breast cancer. The agreement provides for an upfront payment of $70 million plus $15 million upon completion of certain transition activities, in addition to up to $320 million in milestones and tiered royalties in the mid-teens to mid-twenties percent range. Rigel will handle launch and commercialization in the U.S. and retains global rights with options to grant sublicenses outside the U.S. Arvinas reported Q1 EPS of -$0.90 and said its cash runway extends into the second half of 2028; closing of the transaction is subject to regulatory approvals. » More on de.investing.com
FDA approves Arvinas breast cancer drug VEPPANU – stock jumps sharply

The FDA has approved VEPPANU (vepdegestrant) for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced/metastatic breast cancer after at least one line of endocrine therapy. The approval is considered the first for a PROTAC protein degrader and was granted ahead of the PDUFA date of June 5, 2026. After trading resumed, the Arvinas share rose intraday by up to 13%. » More on de.investing.com

Financials

In the last quarter, ARVINAS INC. DL-,001 had revenue of €218.79M and net profit of €148.43M

(EUR)	Jun 2026	YoY
Revenue	218.79M	1,051.24%
Gross profit	210.9M	1,009.75%
Net profit	148.43M	385.86%
EBITDA	139.58M	373.74%

Fundamentals

Metric	Value
Market capitalization	€511.22M
Number of shares	64.52M
52-week high/low	€12.52 - €6.02
Dividends	No
Beta	1.74
P/E ratio	48.32
PEG ratio	-0.27
P/B ratio	1.06
P/S ratio	1.87

Company profile

Arvinas, Inc. ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich mit der Entdeckung, Entwicklung und Vermarktung von Therapien zum Abbau von krankheitsverursachenden Proteinen beschäftigt. Zu seinen führenden Produktkandidaten gehört Bavdegalutamid, ein PROTAC-Proteinabbauer, der sich in der klinischen Phase I befindet und auf das Androgenrezeptor-Protein (AR) zur Behandlung von Männern mit metastasiertem kastrationsresistentem Prostatakrebs (mCRPC) abzielt; ARV-471, ein PROTAC-Proteinabbauer, der auf das Östrogenrezeptorprotein abzielt, für die Behandlung von Patienten mit metastasierendem ER-positivem/HER2-negativem Brustkrebs; und ARV-766, ein oral bioverfügbarer PROTAC-Proteinabbauer für die Behandlung von Männern mit mCRPC. Das Unternehmen arbeitet mit Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd. und der Bayer AG zusammen. Arvinas, Inc. wurde 2013 gegründet und hat seinen Sitz in New Haven, Connecticut.